1. Scrip
  2. >>Conferences
  3. >>ASCO

ASCO: Merck Calls V940 IO Strategy ‘Pillar’ Amid Positive Melanoma Data

 
• By Alaric DeArment

Follow-up data from Merck & Co./Moderna’s KEYNOTE-942 showed durable responses to V940/Keytruda, while Merck said the therapy plays a leading role in its immuno-oncology strategy.

Merck stand at ASCO 2024
• Source: Scrip

Merck & Co., Inc. sees the individualized neoantigen therapy mRNA-4157, also known as V940, as a key pillar in its oncology development strategy over the next several years, which it said could deliver incremental sales of $20bn by the middle of the next decade, particularly after the presentation of positive follow-up data at the American Society of Clinical Oncology annual meeting.

Merck and partner Moderna, Inc. presented three-year data from the Phase II KEYNOTE-942 study of V940 combined with Keytruda...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

More from Conferences

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.